- Home
- SPNT vs IMVT Comparison
SPNT vs IMVT Comparison
Compare SPNT & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPNT
- IMVT
- Stock Information
- Founded
- SPNT 2011
- IMVT 2018
- Country
- SPNT Bermuda
- IMVT United States
- Employees
- SPNT N/A
- IMVT N/A
- Industry
- SPNT Property-Casualty Insurers
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SPNT Finance
- IMVT Health Care
- Exchange
- SPNT Nasdaq
- IMVT Nasdaq
- Market Cap
- SPNT 2.4B
- IMVT 2.7B
- IPO Year
- SPNT N/A
- IMVT N/A
- Fundamental
- Price
- SPNT $20.14
- IMVT $23.78
- Analyst Decision
- SPNT Buy
- IMVT Buy
- Analyst Count
- SPNT 3
- IMVT 9
- Target Price
- SPNT $24.00
- IMVT $27.71
- AVG Volume (30 Days)
- SPNT 515.4K
- IMVT 2.0M
- Earning Date
- SPNT 10-30-2025
- IMVT 11-10-2025
- Dividend Yield
- SPNT N/A
- IMVT N/A
- EPS Growth
- SPNT N/A
- IMVT N/A
- EPS
- SPNT 1.45
- IMVT N/A
- Revenue
- SPNT $2,859,100,000.00
- IMVT N/A
- Revenue This Year
- SPNT $0.89
- IMVT N/A
- Revenue Next Year
- SPNT $6.87
- IMVT N/A
- P/E Ratio
- SPNT $13.83
- IMVT N/A
- Revenue Growth
- SPNT 6.92
- IMVT N/A
- 52 Week Low
- SPNT $13.26
- IMVT $12.72
- 52 Week High
- SPNT $21.03
- IMVT $29.49
- Technical
- Relative Strength Index (RSI)
- SPNT 69.38
- IMVT 65.27
- Support Level
- SPNT $17.71
- IMVT $21.43
- Resistance Level
- SPNT $20.47
- IMVT $24.10
- Average True Range (ATR)
- SPNT 0.54
- IMVT 1.53
- MACD
- SPNT 0.16
- IMVT -0.15
- Stochastic Oscillator
- SPNT 90.05
- IMVT 52.83
About SPNT SiriusPoint Ltd.
SiriusPoint Ltd provides property and casualty reinsurance coverage to insurance and reinsurance companies in the United States, Canada, Bermuda, the United Kingdom, and Europe. The company operates through two operating segments: Reinsurance and Insurance & Services. The company's product portfolio consists of reinsurance contracts for property insurance including both residential and commercial properties, workers' compensation, personal automobile, businesses' general liability insurance, professional liability insurance to protect professional advisors and service providers, agriculture insurance, and mortgage insurance. The majority of the revenue is generated from its Insurance & Services segment.
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.